No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 1.1x · 10Y median 42.9x · 2nd percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 27
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:20:33.917Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Aligos Therapeutics, Inc. (ALGS) stock was $5.40 as of Oct 5, 2026, 4:00 PM EDT, down 2.53% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -46.2% · 3-year avg -34.8%/yr · 5-year avg -57.1%/yr
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases.
Biotechnology · South San Francisco, CA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-2.44
Revenue Est.
$4.85M
Last Quarter Results
EPS
$-0.14
vs Estimate
$-1.24
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ALGS | $33.42M | $5.40 | -2.53% | -46.22% | -57.15% | N/A | N/A |
| 2GRCE | $33.52M | $2.06 | -0.48% | -31.89% | N/A | N/A | vs ALGS |
| 3BYSI | $32.32M | $0.79 | -0.17% | -54.91% | -44.30% | N/A | vs ALGS |
| 4EUDA | $32.31M | $17.30 | +0.37% | -61.04% | N/A | N/A | vs ALGS |
| 5BDMD | $31.36M | $0.74 | -1.09% | -63.41% | N/A | N/A | vs ALGS |
| 6ARAY | $35.89M | $0.30 | +7.37% | -82.00% | -39.94% | -25.77% | vs ALGS |
forward FY estimate
N/A
$27.78M
vs Estimate
$24.68M
Consensus Rating
Based on 8 analysts
Average Price Target
$52.38
+869.9% upside
Low
$20.00
Current
$5.40
High
$175.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-2.52 | $-2.19 | $-1.85 | 4 |
| Quarter ending Dec 2026 | $-1.97 | $-1.87 | $-1.76 | 4 |
| Quarter ending Mar 2027 | $-1.63 | $-1.63 | $-1.63 | 1 |
| Quarter ending Jun 2027 | $-1.66 | $-1.66 | $-1.66 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-6.85 | $-6.30 | $-5.93 | 5 |
| FY 2027 | $-6.70 | $-5.18 | $-3.86 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $4.85M | $4.85M | $4.85M | 4 |
| Quarter ending Dec 2026 | $537500.00 | $537500.00 | $537500.00 | 7 |
| Quarter ending Mar 2027 | $220000.00 | $220000.00 | $220000.00 | 3 |
| Quarter ending Jun 2027 | $220000.00 | $220000.00 | $220000.00 | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $34.30M | $35.99M | $37.67M | 6 |
| FY 2027 | $3.67M | $4.07M | $5.52M | 5 |
